DXM Abuse Prevention (DAP) Act

Authorize The DXM Abuse Prevention (DAP) Act!

Provisions of DAP Act

The DAP Act would amend the Federal Food, Drug, and Cosmetic Act To:

  • Prohibit the sale—both retail and online—of Over The Counter (OTC) medicines containing Dextromethorphan (DXM) to individuals under age 18. Enacting this restriction at the federal level would reduce the potential for abuse of DXM and establish a clear, consistent, nationwide standard for compliance.
  • Restrict Sales of Raw Dextromethorphan to ensure that only legitimate entities registered with the FDA or comparable state agencies can purchase raw, unfinished (bulk) DXM, the active form of the ingredient.  Currently, there are no national sales or purchase restrictions for the acquisition of bulk DXM.